Reading Time: < 1 minute
Featured content in this Issue:
Canada’s First Published Psilocybin Trial: Includes Patients with BDII and Personality Disorders, Employs Flexible Repeat Dosing Protocol
University of Maryland Joins Terran Biosciences’ Complaint Against Compass Pathways
Further Reading & Other Stories
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.